Zai Lab Grants New Share Options and RSUs Under 2024 Equity Plan

An update from Zai Lab Ltd ( (HK:9688) ) is now available.

Zai Lab has granted new equity awards under its 2024 Equity Incentive Plan, issuing 8,000 share options representing 80,000 underlying shares to four employee participants and 12,344 restricted share units representing 123,440 underlying shares to nine employees. The options, priced at US$19.48 per ADS, vest over four years without performance targets or clawback provisions, a structure the board’s compensation committee says is consistent with market practice and designed to retain talent, potentially leading to incremental dilution but aligning employee interests with long-term shareholder value.

The share options carry a ten-year validity period and will lapse upon expiry or earlier termination of employment, reinforcing retention incentives over time. The restricted share units are granted at no purchase price, using prevailing NASDAQ and Hong Kong share prices as reference points, underscoring Zai Lab’s ongoing use of equity-based compensation to strengthen its competitive position in recruiting and retaining key staff in the biopharmaceutical sector.

The most recent analyst rating on (HK:9688) stock is a Hold with a HK$15.50 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.

More about Zai Lab Ltd

Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong and on Nasdaq. The company focuses on developing and commercializing innovative medicines, with its shares traded in the form of American depositary shares (ADSs) in the U.S. and ordinary shares on the Hong Kong Stock Exchange, reflecting a dual-market investor base.

Average Trading Volume: 10,478,187

Technical Sentiment Signal: Sell

Current Market Cap: HK$15.41B

See more data about 9688 stock on TipRanks’ Stock Analysis page.